Metformin Vs Semaglutide for Weight Loss: Surprising Insights

The main difference between Metformin and Semaglutide is the mechanism of action. Semaglutide loses weight quicker than Metformin and shows more noticeable weight loss results.

Medically Reviewed By Mostafa Elhennawy MS, Pharm D

Losing weight is hard, and lifestyle changes alone aren’t always enough. So, to beat obesity, many people consider weight loss drugs like Metformin and Semaglutide. 

Metformin is primarily used for diabetes but it’s also taken for weight loss. The results are usually modest. In contrast, Semaglutide, widely endorsed by celebrities and supported by clinical trials, offers more substantial weight loss results. 

Now, deciding between Metformin vs. Semaglutide for weight loss involves weighing each medication’s benefits and side effects, as both impact individual health outcomes differently. This article compares Metformin and Semaglutide’s profiles to help you find the best fit for your weight loss journey.

About the Experts

We champion clinical excellence through evidence-based, personalized care. We are also commited to affordable clinically-led care for everyone. With features like same day doctor appointments, judgement free care, 24/7 medical chat support, 50+ pharmacy providers, free shipping we are on to something.
semaglutide

Semaglutide

starting at $248 /mo

Why is Semaglutide getting so popular right now?

Because it works. 92% members have achieved lasting weight loss.

Metformin Vs. Semaglutide: Which One is Better for Weight Loss?

The main difference between Metformin and Semaglutide is the mechanism of action. Semaglutide loses weight quicker than Metformin and shows more noticeable weight loss results.  

There are other distinctions between the two weight loss drugs that are summarized in the table below:

Metformin Semaglutide
Chemical composition Biguanide drug GLP-1 receptor agonist
Mechanism of Action Reducing hepatic glucose production, enhancing glucose absorption by skeletal muscle, diminishing intestinal absorption, and enhancing insulin sensitivity Boosting insulin release, decreasing glucagon release, slowing down gastric emptying, and promoting satiety while simultaneously reducing the brain’s reward response to food
Effectiveness Modest weight loss Significant weight loss
Side effects GI issues, decreased vitamin B12 levels, and lactic acidosis GI issues, pancreatitis, gallstones, hypoglycemia, kidney failure, allergic reactions, vision changes, tachycardia, depression, and suicidal ideation
Cost $968.52-$1,349.02/package $11 for 30 tablets/1000 mg dosage
Accessibility Hard Hard
Usage Guidelines There is no labeling information about what dose should be prescribed. The typical maintenance dose for weight loss is 2.4 mg, administered weekly.

Check out the following subsections to get a more thorough explanation of each difference.

Weight Loss Reviews

Chemical Composition

Metformin and Semaglutide differ in molecular structures and belong to different drug classes. Because of this, they have different pharmacokinetic profiles, meaning that one weight loss medication is more efficient. 

Metformin is a biguanide drug derived from the bushy perennial Goat’s rue found in temperate grassland regions of Asia and Europe. Semaglutide, by contrast, is a peptide similar to the hormone GLP-1 released in the gastrointestinal tract in response to eating.

Related articles

Mechanisms of Action

Metformin lowers basal and postprandial blood glucose levels by reducing hepatic glucose production and enhancing glucose absorption by skeletal muscle. It also diminishes intestinal absorption and improves insulin sensitivity. 

On the other hand, Semaglutide reduces appetite by signaling to the brain that a person has eaten. This produces more insulin and decreases glucagon, which improves blood glucose control. Semaglutide leads to weight loss by making a person feel fuller for longer.

Effectiveness

Metformin can reduce BMI by about one unit, which is minimal for a weight loss drug. Patients who lost over 5% of body weight in the first year maintained an average 6.2% weight loss over 6 to 15 years. Semaglutide, however, is more effective, reducing body weight by up to 15%

In a study of 2,000 obese adults, those taking Semaglutide with diet and exercise lost significantly more: half lost 15%, and nearly one-third lost 20% of their body weight, while lifestyle changes alone led to just 2.4% weight loss.

Side Effects

Metformin commonly causes gastrointestinal issues. Chest discomfort, headache, diaphoresis, hypoglycemia, weakness, decreased vitamin B12 levels, and lactic acidosis are less common.

Semaglutide’s side effects include gastrointestinal issues, pancreatitis, gallstones, hypoglycemia, kidney failure, allergic reactions, vision changes, tachycardia, depression, and suicidal ideation.

The patient should consult the healthcare provider before acquiring a prescription for Semaglutide or Metformin.

Cost and Accessibility

The cost of Metformin and Semaglutide varies by treatment plan, insurance, and pharmacy discounts. Metformin, a generic drug, costs around $11 for 30 tablets (1000 mg). In contrast, Novo Nordisk’s patented Semaglutide is much pricier: Ozempic® and Rybelsus® cost $968.52 for a 28-day supply, while Wegovy® costs $1,349.02. Insurance can significantly reduce Semaglutide costs, but many still face high out-of-pocket expenses.

Usage Guidelines

The starting dose of Semaglutide is 0.25 mg weekly for the first month, gradually increasing to a typical weight loss dose of 2.4 mg. Unlike Semaglutide, which is injected, Metformin is taken orally in three forms: oral suspension, immediate-release, and extended-release tablets.

Initial doses for immediate-release Metformin are 500 mg twice daily or 850 mg once daily, increasing as tolerated, with a maintenance dose of 2000 mg/day. Extended-release Metformin starts at 500-1000 mg daily, with a maximum of 2000 mg/day. While Metformin isn’t approved for weight loss, studies suggest 1500 mg may reduce weight.

Frequently Asked Questions

Can You Take Metformin and Semaglutide Together?

Yes, it is safe to take Semaglutide and Metformin together. The differences between Metformin and Semaglutide in how they control blood sugar mean that combining the two offers complementary effects for improved glycemic control and weight management. Some people suffer mild to moderate gastrointestinal side effects from Metformin, which are not worsened by adding Semaglutide.

Does Insurance Cover Semaglutide and Metformin for Weight Loss?

No, insurance does not cover Semaglutide and Metformin for weight loss, even though obesity is linked to several health risks. For this, there have to be obesity-related medical problems. Also, taking Metformin for weight loss is regarded as an off-label use because it is approved for diabetes. 

Are Semaglutide and Metformin Safe for Long-term Use?

Yes, Semaglutide and Metformin are generally safe for long-term use. However, healthcare professionals must check the kidneys and vitamin B12 levels at least once a year, especially if the patient taking Metformin is tired, breathless, and faint. Also, there is a minimal risk of gallbladder disease associated with longer-term use of Semaglutide.

Key Takeaways

  • Semaglutide is very effective at controlling appetite and weight, while Metformin is linked to a slight decrease in body weight. 
  • The mechanisms of action, efficacy, dosage forms, and strengths of Metformin and Semaglutide are very different.
  • Semaglutide and Metformin are considered safe for long-term use. However, regular follow-up is important to monitor for rare adverse effects and ensure safe and effective use over the long term.
  • Metformin is more affordable than branded Semaglutide.

Sources

Brandfon S, Eylon A, Khanna D, Parmar MS. Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges. Cureus. 2023 Oct 7;15(10):e46623. doi: 10.7759/cureus.46623. PMID: 37937009; PMCID: PMC10626572.

Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023 Mar 20;58:101882. doi: 10.1016/j.eclinm.2023.101882. PMID: 36992862; PMCID: PMC10041469.

Metformin

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024 

Han SH, Safeek R, Ockerman K, Trieu N, Mars P, Klenke A, Furnas H, Sorice-Virk S. Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis. Aesthet Surg J. 2023 Dec 14;44(1):60-67. doi: 10.1093/asj/sjad211. PMID: 37402640.

Andraos J, Smith SR, Tran A, Pham DQ. Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes. J Diabetes Metab Disord. 2024 Mar 25;23(1):385-394. doi: 10.1007/s40200-024-01406-6. PMID: 38932889; PMCID: PMC11196467.

Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017 Sep;60(9):1577-1585. doi: 10.1007/s00125-017-4342-z. Epub 2017 Aug 3. PMID: 28776086; PMCID: PMC5552828.

Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology. 2011 Dec;152(12):4610-9. doi: 10.1210/en.2011-1485. Epub 2011 Oct 4. PMID: 21971158.

Pharmaceutical Roots: Metformin – could leading antidiabetic become ‘The aspirin of the 21st century?’

Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ, Pi-Sunyer X, Kalyani RR, Franks PW, Srikanthan P, Gadde KM; Diabetes Prevention Program Research Group. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019 May 21;170(10):682-690. doi: 10.7326/M18-1605. Epub 2019 Apr 23. Erratum in: Ann Intern Med. 2020 Sep 15;173(6):508. doi: 10.7326/L20-0029. PMID: 31009939; PMCID: PMC6829283.

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.

Pu R, Shi D, Gan T, Ren X, Ba Y, Huo Y, Bai Y, Zheng T, Cheng N. Effects of metformin in obesity treatment in different populations: a meta-analysis. Ther Adv Endocrinol Metab. 2020 May 21;11:2042018820926000. doi: 10.1177/2042018820926000. PMID: 32499908; PMCID: PMC7243386.

Moiz A, Levett JY, Filion KB, Peri K, Reynier P, Eisenberg MJ. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Cardiol. 2024 Jul 1;222:121-130. doi: 10.1016/j.amjcard.2024.04.041. Epub 2024 Apr 26. PMID: 38679221.

Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. Curr Obes Rep. 2019 Jun;8(2):156-164. doi: 10.1007/s13679-019-00335-3. PMID: 30874963; PMCID: PMC6520185.

Li J, Li K, Liu Z, Yu H, Zhang J. Efficacy and safety of semaglutide combined with metformin in treating T2DM with overweight or obesity: a systematic review and meta-analysis. Am J Transl Res. 2024 Aug 15;16(8):3545-3556. doi: 10.62347/RYLN5360. PMID: 39262717; PMCID: PMC11384358.

Hausner H, Derving Karsbøl J, Holst AG, Jacobsen JB, Wagner FD, Golor G, Anderson TW. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Clin Pharmacokinet. 2017 Nov;56(11):1391-1401. doi: 10.1007/s40262-017-0532-6. PMID: 28349387; PMCID: PMC5648738.

More articles from Jack&Jill

Select your store

United States
Canada

I’m in Canada.

Get matched with licensed treatments and health care providers, where you live.